Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Editor’s Pick: Five Healthcare News Headlines for October 20 - October 31
November 5, 2014
- PMDA Establishes Office of Generic Drugs to Expedite Review and Consultation for Generic Drugs
November 4, 2014
- Cabinet OKs Appointment of Keio Prof as Japan NIH Head
October 31, 2014
- MHLW to Issue Notification with Survey Form on Adverse Reactions to HPV Vaccines
October 31, 2014
- Lantus Biosimilars Likely to Be OKed by Year-End: First Committee
October 30, 2014
- Welfare Recipients Should Pay Difference between Generic and Branded Drug Prices: MOF
October 29, 2014
- Health Ministry Shares Views on PI Studies for Japanese Patients
October 29, 2014
- Risk of Fulminant Hepatitis Added to Lyrica Package Insert: MHLW
October 29, 2014
- PAFSC Second Committee Backs Approval of Janssen’s Combination Tablet for HIV
October 28, 2014
- Off-Label Use of Avigan Allowed for Ebola Treatment: Health Ministry Panel
October 28, 2014
- Janssen Ordered to Issue Blue Letter on Sovriad after Three Deaths
October 28, 2014
- MHLW Official Says Price Settlement Rate Apparently Topped 90% at End of Sept., but Annual Revisions Unrealistic for “Exhausted” Wholesalers
October 28, 2014
- Cultured Epidermal Autograft JACE Recommended for Orphan Designation
October 27, 2014
- Health Ministry Panel Agrees to Regulate Clinical Research by Law
October 24, 2014
- MHLW Orders Revision of Package Insert for Xtandi
October 24, 2014
- MHLW Orders Revision of Package Inserts for Acetaminophen
October 24, 2014
- Trade Groups Seek Insurance Coverage for Conditionally Approved Regenerative Medicine Products
October 24, 2014
- Chuikyo OKs New Review Organs for Regenerative Medicines and Medical Devices under Senshin-Iryo System
October 24, 2014
- Chuikyo Begins Discussions on Patient-Initiated Mixed-Care System
October 24, 2014
- Online Document Filings for Healthcare Product Import/Export Possible from November
October 23, 2014
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…